Nirmal Bang has maintained its ‘Buy’ rating on Ranbaxy Laboratories to achieve a target between Rs 225-240 within 1-5 days.

Interested traders can buy the stock on dips with a stop loss of Rs 210.

Shares of the company, on Wednesday (April 15), closed at Rs 199.85 on the Bombay Stock Exchange (BSE). The share price has seen a 52-week high of Rs 613.70 and a low of Rs 133.15 on BSE.

The Hyderabad based, Natco Pharma, on Wednesday, announced that it has signed up a deal with pharmaceutical major Dr Reddy's Laboratories.

Under the deal, both the firms will develop, manufacture and sell generic cancer products jointly.

However, the financial details of the deal are not yet known.

Pfizer Inc., the world's leading research-based pharmaceutical company, announced that it has decided to buy additional 33.77% equity stake in its Indian division in order to increase its holding stake to 75%.  

The New York based pharmaceutical major said that it will spend around Rs 6.8 billion on the deal.

The acquirement will be done through Pfizer’s wholly-owned arm, Pfizer Investments Netherlands B.V.

The company seeks to purchase additional stake at Rs 675 per share.

Pharmaceutical company Jubilant Organosys on Thursday said it has joined hands with a Finland-based firm Orion for the discovery of drugs.

The company stated in a release, that its two subsidiaries Jubilant Biosys Ltd (Bangalore based) and Jubilant Chemsys Ltd (Noida based), has entered into a pact with a Finland-based firm Orion.

Under this "Hybrid & Integrated" arrangement, Orion will have the option of utilizing resources flexibly from both Jubilant Biosys Ltd and Jubilant Chemsys Ltd based on the requirements of its drug discovery projects.

Suven Life Sciences, a Drug Discovery and development company, has finished the phase I clinical trial for its new molecule, SUVN 502 in healthy volunteers.

In a filing, Suven Life Sciences said, “The company has completed its Phase I multiple ascending dose study of SUVN-502 in healthy volunteers.”

The commercialization of generic equivalents of Lanthanum Carbonate - Fosrenol(r) - tablets is on the cards, thanks to collaboration between the Mumbai-based pharma biggie, Lupin, and the Hyderabad-based integrated pharmaceutical and bulk chemicals' manufacturer, Natco Pharma.

Talking about the Lupin-Natco collaboration for Fosrenol(r), a Natco spokesperson said that the accord will help Natco battle a patent lawsuit recently filed by the Fosrenol(r) innovator - the UK-based firm, Shire Plc.